RWD293 COST-EFFECTIVENESS OF DOSTARLIMAB FOR ADVANCED OR RECURRENT MSI-H/DMMR ENDOMETRIAL CANCER IN ANTI-PD1/PD-L1 NAïVE PATIENTS: A TAIWAN'S NATIONAL HEALTH INSURANCE PERSPECTIVE
Abstract
Authors
Hsiao-Tung Tsai Chi-Yun Wu Fei-Yuan Sharon Hsiao Yi Wen Chang Liang-Yi Lin Chyong-Huey Lai Shih-Tsung Huang Yao-Chun Wen